Reata Pharma (RETA) Appoints Steven W. Ryder to its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. LSTR
9. UPS
10. KIDS

Go back to Reata Pharma (RETA) Appoints Steven W. Ryder to its Board

Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

July 11, 2022 6:45 AM EDT

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, or we), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022.

We are thrilled to welcome Dr. Ryder to Reatas board, said Warren Huff, Reatas Chief Executive Officer. He is joining us at a critical point in Reatas development with our New Drug Application under review with the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreichs ataxia. His knowledge will be... More